Tevogen

Q2 FY2026 EarningsFY26 Q2 results showed zero revenue and a loss from operations of -$5.66M, outperforming the consensus EBIT expectation of -$12.5M. GAAP Net Loss of -$5.76M also beat the consensus of -$12.5M, while GAAP EPS of -$1.52 significantly exceeded the -$2.50 expectation. Despite these beats, the company remains in a pre-revenue stage with a $8.9M stockholders' deficit and relies on related-party financing and grants to maintain its 12-month liquidity runway.